twit 25   linkedin 25

16 / Feb 03

ENYO Pharma announces closing of a €22 million funding round

ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, today announced that it has secured a €22 million Series A financing round. The investment is intended to help the company roll out its clinical hepatitis-B programme more quickly.
The deal was led by Sofinnova Partners, alongside Morningside and Bpifrance via its fund InnoBio, and should enable ENYO Pharma to conduct Phase I trials in the first half of 2016, and phase II trials on chronic hepatitis B sufferers should follow by 2017.
Viral infections represent a major public health and socioeconomic problem. According to the WHO, more than 350 million people with chronic hepatitis B infections are awaiting treatment, half of whom are in Asia and mainly in China.

About NewCap

As a specialist in investor relations and strategic communication advice, NewCap advises and supports its clients regarding their sectoral, scientific, institutional and financial communication strategies.

CONTACT

contact 01Address :
21, place de la Madeleine - 75008 Paris

contact 02Phone :
+33 (0)1 44 71 94 94

contact 03Email :
infos(at)newcap.fr